CA
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVECOVER ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

CA Cancer J Clin 1980; 30:158-181
doi: 10.3322/canjclin.30.3.158
© 1980 American Cancer Society
This Article
Right arrow Full Text (PDF) Freely available
Right arrow Submit a letter to the editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Smithson, W. A.
Right arrow Articles by Burgert, E. O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Smithson, W. A.
Right arrow Articles by Burgert, E. O., Jr.

CA: A Cancer Journal for Clinicians, Vol 30, 158-181, Copyright © 1980 by American Cancer Society

Childhood Acute Lymphocytic Leukemia

W. A. Smithson M.D.1, G. S. Gilchrist M.B., B.Ch.2, and E. O. Burgert Jr. M.D.3

1 Consultant in Pediatric Hematology-Oncology, Mayo Clinic and Mayo Foundation, and Assistant Professor of Pediatrics, Mayo Medical School, Rochester, Minnesota.
2 Vice Chairman of Pediatrics and Consultant in Pediatric Hematology-Oncology, Mayo Clinic and Mayo Foundation, and Professor of Pediatrics, Mayo Medical School, Rochester, Minnesota.
3 Consultant in Pediatric Hematology-Oncology, Mayo Clinic and Mayo Foundation, and Professor of Pediatrics, Mayo Medical School, Rochester, Minnesota.

At present, significant numbers of children with ALL enjoy prolonged survival without serious sequelae. All children should be given the benefit of treatment under the supervision of physicians experienced in childhood cancer. Risk factors should be properly assessed and children at high risk placed in innovative programs. Longterm follow-up of patients is essential to detect, as early as possible, potentially prohibitive toxicity.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVECOVER ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1980 by American Cancer Society.